Provided by Tiger Fintech (Singapore) Pte. Ltd.

Innate Pharma SA

1.96
+0.0000
Volume:742.00
Turnover:1.45K
Market Cap:164.27M
PE:-4.34
High:1.96
Open:1.96
Low:1.96
Close:1.96
Loading ...

Innate Pharma Price Target Maintained With a $11.50/Share by HC Wainwright & Co.

Dow Jones
·
15 Nov 2024

Evercore ISI Sticks to Its Buy Rating for Innate Pharma (IPHA)

TIPRANKS
·
14 Nov 2024

Discover 3 Promising Penny Stocks With Over US$90M Market Cap

Simply Wall St.
·
13 Nov 2024

Innate Pharma's Revenue For The Nine Months €10.2M, Down From €36.5M YoY; Cash €96.4M

Benzinga
·
13 Nov 2024

Press Release: Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Dow Jones
·
13 Nov 2024

Innate Pharma Price Target Maintained With a $11.50/Share by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

Business Wire
·
08 Nov 2024

Press Release: Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

Dow Jones
·
07 Nov 2024

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Business Wire
·
29 Oct 2024

Innate Pharma Names Jonathan Dickinson CEO, Executive Board Chairman

Dow Jones
·
14 Oct 2024

Innate Pharma appoints Jonathan Dickinson as CEO

TIPRANKS
·
14 Oct 2024

Innate Pharma Names Jonathan Dickinson as New CEO, Chairman

MT Newswires Live
·
14 Oct 2024

Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday

Benzinga
·
14 Oct 2024

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

Business Wire
·
14 Oct 2024

Leerink Partners Reaffirms Their Buy Rating on Innate Pharma (IPHA)

TIPRANKS
·
08 Oct 2024

Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

Business Wire
·
30 Sep 2024